[go: up one dir, main page]

MX2010010300A - Formas de sal de inhibidores del objetivo de rapamicina en mamiferos. - Google Patents

Formas de sal de inhibidores del objetivo de rapamicina en mamiferos.

Info

Publication number
MX2010010300A
MX2010010300A MX2010010300A MX2010010300A MX2010010300A MX 2010010300 A MX2010010300 A MX 2010010300A MX 2010010300 A MX2010010300 A MX 2010010300A MX 2010010300 A MX2010010300 A MX 2010010300A MX 2010010300 A MX2010010300 A MX 2010010300A
Authority
MX
Mexico
Prior art keywords
salt forms
mtor inhibitor
inhibitor salt
mtor
formulation
Prior art date
Application number
MX2010010300A
Other languages
English (en)
Inventor
Arlindo L Castelhano
Kristen Michelle Mulvihill
Gary C Visor
Josef A Rechka
Original Assignee
Osi Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Osi Pharm Inc filed Critical Osi Pharm Inc
Publication of MX2010010300A publication Critical patent/MX2010010300A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Formas de sales de inhibidores de mTOR de la Fórmula (I) (ver fórmula (I)) y métodos de preparación, formulación, y uso en el tratamiento de enfermedades.
MX2010010300A 2008-03-19 2009-03-18 Formas de sal de inhibidores del objetivo de rapamicina en mamiferos. MX2010010300A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US7006208P 2008-03-19 2008-03-19
PCT/US2009/037505 WO2009117482A1 (en) 2008-03-19 2009-03-18 Mtor inhibitor salt forms

Publications (1)

Publication Number Publication Date
MX2010010300A true MX2010010300A (es) 2010-10-26

Family

ID=40597405

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2010010300A MX2010010300A (es) 2008-03-19 2009-03-18 Formas de sal de inhibidores del objetivo de rapamicina en mamiferos.

Country Status (12)

Country Link
US (1) US8557814B2 (es)
EP (1) EP2276763A1 (es)
JP (1) JP2011515410A (es)
KR (1) KR20110017845A (es)
CN (1) CN101977912A (es)
AU (1) AU2009225614A1 (es)
BR (1) BRPI0910232A2 (es)
CA (1) CA2716924A1 (es)
EA (1) EA018144B1 (es)
MX (1) MX2010010300A (es)
WO (1) WO2009117482A1 (es)
ZA (1) ZA201006641B (es)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101316845A (zh) * 2005-11-17 2008-12-03 Osi医药有限公司 稠合双环mTOR抑制剂
EP2178563A2 (en) * 2007-07-06 2010-04-28 OSI Pharmaceuticals, Inc. Combination anti-cancer therapy comprising an inhibitor of both mtorc1 and mtorc2
CN101977912A (zh) 2008-03-19 2011-02-16 Osi医药有限公司 mTOR抑制剂的盐形式
WO2011049625A1 (en) 2009-10-20 2011-04-28 Mansour Samadpour Method for aflatoxin screening of products
RS56432B1 (sr) 2009-11-05 2018-01-31 Rhizen Pharmaceuticals S A Novi benzopiran modulatori kinaze
JP2013522215A (ja) 2010-03-09 2013-06-13 オーエスアイ・ファーマシューティカルズ，エルエルシー 組合わせ抗癌療法
UA106692C2 (uk) 2011-02-23 2014-09-25 Пфайзер Інк. ІМІДАЗО[5,1-f][1,2,4]ТРИАЗИНИ ДЛЯ ЛІКУВАННЯ НЕВРОЛОГІЧНИХ РОЗЛАДІВ
MX365160B (es) 2011-05-04 2019-05-24 Rhizen Pharmaceuticals Sa Compuestos novedosos como moduladores de proteína cinasas.
WO2013152342A1 (en) 2012-04-06 2013-10-10 OSI Pharmaceuticals, LLC Anti-cancer mtor inhibitor and anti-androgen combination
SG11201408821SA (en) 2012-07-04 2015-01-29 Rhizen Pharmaceuticals Sa Selective pi3k delta inhibitors
US9688682B2 (en) * 2013-07-16 2017-06-27 Dr. Reddy's Laboratories Limited Crystalline forms of pemetrexed tromethamine salts
WO2015134711A1 (en) * 2014-03-06 2015-09-11 Ptc Therapeutics, Inc. Pharmaceutical compositions and salts of a 1,2,4-oxadiazole benzoic acid
US9987241B2 (en) 2014-09-25 2018-06-05 The Board Of Regents Of The University Of Oklahoma Enzyme conjugate and prodrug cancer therapy
US10214537B2 (en) 2014-10-22 2019-02-26 Bristol-Myers Squibb Company Bicyclic heteroaryl amine compounds
WO2016064958A1 (en) 2014-10-22 2016-04-28 Bristol-Myers Squibb Company Heteroaryl substituted pyrrolotriazine amine compounds as pi3k inhibitors
US10722484B2 (en) 2016-03-09 2020-07-28 K-Gen, Inc. Methods of cancer treatment
HUE064656T2 (hu) 2016-03-28 2024-04-28 Incyte Corp Pirrolotriazin vegyületek mint TAM inhibitorok
US11446365B2 (en) 2017-08-09 2022-09-20 The Board Of Regents Of The University Of Oklahoma Antimalarial enzyme conjugates, kits containing same, and methods of producing and using same
FR3075794A1 (fr) 2017-12-21 2019-06-28 Galderma Research & Development Nouveaux composes inhibiteurs de mtor
FR3075795A1 (fr) 2017-12-21 2019-06-28 Galderma Research & Development Nouveaux composes inhibiteurs de mtor
MX2021007536A (es) * 2018-12-21 2021-09-23 Les Laboratoires Servier Sas Formas de sal y cristalinas de un compuesto organico y composiciones farmaceuticas del mismo.

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996010028A1 (en) * 1994-09-29 1996-04-04 Novartis Ag PYRROLO[2,3-d]PYRIMIDINES AND THEIR USE
ID24653A (id) * 1997-03-19 2000-07-27 Basf Ag Zat-zat terapi
US7863444B2 (en) * 1997-03-19 2011-01-04 Abbott Laboratories 4-aminopyrrolopyrimidines as kinase inhibitors
US6383790B1 (en) * 1999-01-11 2002-05-07 Princeton University High affinity protein kinase inhibitors
US6921763B2 (en) * 1999-09-17 2005-07-26 Abbott Laboratories Pyrazolopyrimidines as therapeutic agents
AU2002333524A1 (en) * 2001-09-11 2003-03-24 Glaxosmithkline K.K. Furo-and thienopyrimidine derivatives as angiogenesis inhibitors
WO2005037836A2 (en) * 2003-10-15 2005-04-28 Osi Pharmaceuticals, Inc. Imidazo ‘1, 5 - a ! pyrazine tyrosine kinase inhibitors
AU2004295291A1 (en) * 2003-10-27 2005-06-16 Smithkline Beecham Corporation Nucleoside compounds for treating viral infections
WO2005047289A1 (en) * 2003-11-17 2005-05-26 Pfizer Products Inc. Pyrrolopyrimidine compounds useful in treatment of cancer
CN102924458B (zh) * 2004-04-02 2014-11-05 Osi制药有限责任公司 6,6-双环取代的杂双环蛋白激酶抑制剂
AR053090A1 (es) * 2004-07-20 2007-04-25 Osi Pharm Inc Imidazotriazinas como inhibidores de proteina quinasas y su uso para la preparacion de medicamentos
EP1831225A2 (en) * 2004-11-19 2007-09-12 The Regents of the University of California Anti-inflammatory pyrazolopyrimidines
CN101316845A (zh) * 2005-11-17 2008-12-03 Osi医药有限公司 稠合双环mTOR抑制剂
AR057960A1 (es) * 2005-12-02 2007-12-26 Osi Pharm Inc Inhibidores de proteina quinasa biciclicos
CN101389630A (zh) * 2005-12-29 2009-03-18 艾博特公司 蛋白激酶抑制剂
EP1981890A2 (en) * 2006-01-25 2008-10-22 OSI Pharmaceuticals, Inc. UNSATURATED mTOR INHIBITORS
WO2007106503A2 (en) * 2006-03-13 2007-09-20 Osi Pharmaceuticals, Inc. Combined treatment with an egfr kinase inhibitor and an agent that sensitizes tumor cells to the effects of egfr kinase inhibitors
EA200870385A1 (ru) 2006-03-29 2009-04-28 Фолдркс Фармасьютикалз, Инк. Ингибирование токсичности альфа-синуклеина
KR20130087054A (ko) * 2006-04-04 2013-08-05 더 리젠트스 오브 더 유니이버시티 오브 캘리포니아 키나제 길항물질
DE102006016426A1 (de) 2006-04-07 2007-10-11 Merck Patent Gmbh Neuartige Cyclobutyl-Verbindungen als Kinase-Inhibitoren
WO2009009016A1 (en) * 2007-07-06 2009-01-15 Osi Pharmaceuticals, Inc. Combination anti-cancer therapy
EP2178563A2 (en) * 2007-07-06 2010-04-28 OSI Pharmaceuticals, Inc. Combination anti-cancer therapy comprising an inhibitor of both mtorc1 and mtorc2
MX2010004074A (es) * 2007-10-15 2010-07-02 Astrazeneca Ab Combinacion 059.
CN101977912A (zh) 2008-03-19 2011-02-16 Osi医药有限公司 mTOR抑制剂的盐形式
JP2012532882A (ja) 2009-07-09 2012-12-20 オーエスアイ・ファーマシューティカルズ，エルエルシー 置換３−アミノ−５−オキソ−４，５−ジヒドロ−［１，２，４］トリアジンのための製法
US20120128670A1 (en) 2009-07-31 2012-05-24 OSI Pharmaceuticals, LLC mTOR INHIBITOR AND ANGIOGENESIS INHIBITOR COMBINATION THERAPY

Also Published As

Publication number Publication date
EA018144B1 (ru) 2013-05-30
EP2276763A1 (en) 2011-01-26
EA201071099A1 (ru) 2011-02-28
JP2011515410A (ja) 2011-05-19
ZA201006641B (en) 2011-05-25
CN101977912A (zh) 2011-02-16
CA2716924A1 (en) 2009-09-24
US8557814B2 (en) 2013-10-15
US20110015197A1 (en) 2011-01-20
WO2009117482A8 (en) 2010-04-08
KR20110017845A (ko) 2011-02-22
BRPI0910232A2 (pt) 2015-09-29
WO2009117482A1 (en) 2009-09-24
AU2009225614A1 (en) 2009-09-24

Similar Documents

Publication Publication Date Title
MX2010010300A (es) Formas de sal de inhibidores del objetivo de rapamicina en mamiferos.
LTPA2020534I1 (lt) 1-((5-Heteroariltiazol-2-il)aminokarbonil)pirolidin-2-karboksamido dariniai, kaip fosfatidilinozitolio 3-kinazės (PI3K) inhibitoriai, naudingi proliferacinių ligų gydyme
MX349787B (es) Formas de dosis oral que incluyen un agente antiplaqueta y un inhibidor de ácido.
TN2009000400A1 (en) Methods of treating cancer using pyridopyrimidininone inhibitors of pi3k alpha
EA201100030A1 (ru) Пиразольные соединения 436
JO2885B1 (en) Protein kinase inhibitors
MY159230A (en) P38 map kinase inhibitors
TW200738725A (en) Unsaturated mTOR inhibitors
IN2012DN01869A (es)
UA104731C2 (ru) Ингибиторы р38 мар-киназ
EA200970935A1 (ru) Способы лечения с применением хинаксолиновых ингибиторов pi3k-альфа
NZ595572A (en) Inhibitors of pi3 kinase and / or mtor
SV2009003299A (es) Derivados de dihidropiridina de utilidad como inhibidores de la proteina quinasa
EA201170252A1 (ru) Амидофеноксиндазолы в качестве ингибиторов c-мет
WO2012068096A3 (en) Benzoxazepines as inhibitors of pi3k/mtor and methods of their use and manufacture
WO2012068106A3 (en) Benzoxazepines as inhibitors of pi3k/mtor and methods of their use and manufacture
EA201490194A1 (ru) Комбинированная терапия, включающая ингибитор cdk4/6 и ингибитор pi3k для применения в лечении рака
UA99284C2 (ru) ИНГИБИТОРЫ р70 S6-КИНАЗЫ
MD20150085A2 (ro) Inhibitori ai histon-demetilazelor
MX2013004491A (es) Boronatos como inhibidores de arginasa.
MY166653A (en) Derivatives of 1-amino-2-cyclobutylethylboronic acid
WO2011080568A8 (en) Novel pyrimidine compounds as mtor and pi3k inhibitors
BRPI0807717A2 (pt) Inibidores de quinase úteis para o tratamento de doenças mieloproliferativas e outras doenças proliferativas.
UA111075C2 (uk) Триазолопіридинові сполуки як інгібітори кінази рім
EA201100424A1 (ru) Новые ингибиторы

Legal Events

Date Code Title Description
FA Abandonment or withdrawal